Cytokinetics (CYTK) Exchange Rate Effect (2023 - 2026)
Cytokinetics (CYTK) posted quarterly Exchange Rate Effect of -$483000.0 for Q1 2026, down 78.89% year-over-year from -$2.3 million in Q1 2025, and down 352.88% quarter-over-quarter from $191000.0 in Q4 2025.
Powered by 
Analysis
Cytokinetics (CYTK) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Exchange Rate Effect for 4 consecutive years, with -$483000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 78.89% year-over-year to -$483000.0; the TTM figure through Mar 2026 stood at -$928000.0 (down 954.55% YoY), while the FY2025 annual figure was -$715000.0, down 442.11% from the prior year.
- Exchange Rate Effect fell to -$483000.0 in Q1 2026 per CYTK's latest filing, from $191000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $292000.0 in Q4 2024 and bottomed at -$682000.0 in Q2 2025.
- Historically, Exchange Rate Effect has averaged -$100900.0 across 4 years, with a median of -$2000.0 in 2023.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect soared 1560.0% — and 2025, when it plunged 4362.5%.
- Cytokinetics' Exchange Rate Effect stood at -$20000.0 in 2023, then jumped by 1560.0% to $292000.0 in 2024, then slumped by 34.59% to $191000.0 in 2025, then tumbled by 352.88% to -$483000.0 in 2026.
- Business Quant data shows CYTK's Exchange Rate Effect at -$483000.0 in Q1 2026, $191000.0 in Q4 2025, and $46000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | -595,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -595,000.00 |
| Mar 31, 2026 | -483,000.00 |
| Dec 31, 2025 | 191,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | -682,000.00 |
| Mar 31, 2025 | -270,000.00 |
| Dec 31, 2024 | 292,000.00 |
| Sep 30, 2024 | -126,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | -20,000.00 |